Clinical trial
Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys
NCT00441584 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- July 31, 2005
- Completion date
- June 30, 2008
- Enrollment
- 117 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.